Colchicine and risk of hospitalisation due to COVID-19: a population-based study
Sáenz-Aldea et al.,
Colchicine and risk of hospitalisation due to COVID-19: a population-based study,
Journal of Medical Virology, doi:10.1002/jmv.28496
Retrospective 86,652 patients in Spain, showing no significant difference in cases and hospitalization with colchicine use. The different risk for patients prescribed colchicine may not be fully adjusted for.
risk of hospitalization, 8.0% higher, OR 1.08, p = 0.68, treatment 36 of 3,060 (1.2%) cases,
459 of 56,785 (0.8%) controls, case control OR.
|
risk of case, 12.0% higher, OR 1.12, p = 0.68, treatment 140 of 29,817 (0.5%) cases,
459 of 56,875 (0.8%) controls, NNT 9.0, case control OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sáenz-Aldea et al., 13 Jan 2023, retrospective, Spain, peer-reviewed, 8 authors.
Contact:
angel.salgado.barreira@usc.es.
Abstract: | Accepted: 11 January 2023
DOI: 10.1002/jmv.28496
RESEARCH ARTICLE
Colchicine and risk of hospitalization due to COVID‐19:
A population‐based study
María Sáenz‐Aldea1 | Ángel Salgado‐Barreira2,3,4
| Margarita Taracido Trunk2,3,4
María Piñeiro‐Lamas4 | Maria T. Herdeiro5 | Manuel Portela‐Romero6,7 |
Marc Saez8,9
1
|
| Adolfo Figueiras2,3,4
Centro de Salud Dávila, Santander, Spain
2
Department of Preventive Medicine and
Public Health, University of Santiago de
Compostela, Santiago de Compostela, Spain
3
Abstract
Colchicine is one of the most widely studied and best‐known anti‐inflammatory
treatments. This study aimed to assess the effect of colchicine on risk of
Institute of Health Research of Santiago de
Compostela, Santiago de Compostela, Spain
hospitalization due to COVID‐19; and its effect on susceptibility to and severity of
4
the virus in patients with COVID‐19. We carried out a population‐based case‐
Consortium for Biomedical Research in
Epidemiology & Public Health (CIBER en
Epidemiología y Salud Pública‐CIBERESP),
University of Santiago de Compostela,
Santiago de Compostela, Spain
5
Department of Medical Sciences, iBiMED‐
Institute of Biomedicine, University of Aveiro,
Aveiro, Portugal
6
Centro de Salud Concepción Arenal, Santiago
de Compostela, Spain
control study. The following groups were applied: (1) to assess risk of hospitalization,
cases were patients with a positive PCR who were hospitalized due to COVID‐19,
and controls without a positive PCR; (2) to assess susceptibility to COVID‐19, cases
were patients with a positive PCR (hospitalized and non‐hospitalized), and the same
controls; (3) to determine potential severity, cases were subjects with COVID‐19
hospitalized, and controls patients with COVID‐19 nonhospitalised. Different
electronic, linked, administrative health and clinical databases were used to extract
7
Centro de Investigación Biomédica en Red de
Enfermedades Cardiovasculares (CIBERCV),
Santiago de Compostela, Spain
8
data on sociodemographic variables, comorbidities, and medications dispensed. The
study covered 3060 subjects with a positive PCR who were hospitalized, 26 757
Research Group on Statistics, Econometrics
and Health (GRECS), University of Girona,
Girona, Spain
with a positive PCR who were not hospitalized, and 56 785 healthy controls. After
9
colchicine did not modify risk of hospitalization due to COVID‐19 (adjusted odd ratio
CIBER of Epidemiology and Public Health
(CIBERESP), Madrid, Spain
Correspondence
Ángel Salgado‐Barreira, Dto. de Medicina
Preventiva y Salud Pública, Facultad de
Medicina, c/San Francisco s/n, 15786
Santiago de Compostela (A Coruña), Spain.
Email: angel.salgado.barreira@usc.es
Funding information
Instituto de Salud Carlos III
adjustment for sociodemographic variables, comorbidities and other treatments,
[OR] 1.08 [95% confidence interval (CI) 0.76−1.53]), patients' susceptibility to
contracting the disease (adjusted OR 1.12 (95% CI 0.91−1.37)) or the severity of the
infection (adjusted OR 1.03 [95% CI 0.67−1.59]). Our results would neither support
the prophylactic use of colchicine for prevention of the infection or hospitalization in
any type of patient, nor justify the withdrawal of colchicine treatment due to a
higher risk of contracting COVID‐19.
KEYWORDS
colchicine, COVID‐19, hospitalization, susceptibility
1
| INTRODUCTION
availability of vaccines.1 The vaccine hesitancy,2 low vaccination
rates in some countries, 3 it remains of great..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit